Syros Pharmaceuticals Inc SYRS.OQ SYRS.O is expected to show a fall in quarterly revenue when it reports results on October 31 for the period ending September 30 2024
The Cambridge Massachusetts-based company is expected to report a 88.0% decrease in revenue to $450 thousand from $3.76 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for Syros Pharmaceuticals Inc is for a loss of 72 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Syros Pharmaceuticals Inc is $10.00, above its last closing price of $2.11.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | -0.78 | -0.77 | -0.59 | Beat | 23.2 |
Mar. 31 2024 | -0.81 | -0.87 | -0.10 | Beat | 88.5 |
Dec. 31 2023 | -1.31 | -1.14 | -2.18 | Missed | -90.5 |
Sep. 30 2023 | -1.16 | -1.14 | -1.43 | Missed | -25.3 |
Jun. 30 2023 | -1.10 | -1.13 | -1.30 | Missed | -15.2 |
Mar. 31 2023 | -1.10 | -1.09 | -0.85 | Beat | 22 |
Dec. 31 2022 | -1.36 | -1.35 | -0.17 | Beat | 87.4 |
Sep. 30 2022 | -3.91 | -4.01 | -3.21 | Beat | 20 |
This summary was machine generated October 29 at 13:44 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。